Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 9/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.45 |
| ▸ | JAK3 | P52333 | 4/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12761355 | 0.93 | JAK3 (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL2282182 | 0.93 | JAK3 (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL1634119 | 0.92 | JAK3 (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL1635030 | 0.92 | JAK3 (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL1634525 | 0.92 | HTR6 (0.47) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL1636178 | 0.92 | JAK3 (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL2271951 | 0.91 | JAK3 (0.43) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL1633655 | 0.90 | JAK3 (0.41) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL2279235 | 0.90 | JAK3 (0.42) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 | |
| SCHEMBL12761598 | 0.90 | JAK3 (0.41) | PIK3CDPIK3CAPIK3CGPIK3CBJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101945877-B | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | claimed |
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | claimed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | claimed |
| CN-101945877-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2011-01-12 | — | — | CN | claimed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | claimed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | claimed |
| CN-101945877-B | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2247595-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932254-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2247595-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106445-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | PIK3CD 163/4885PIK3CA 293/4885PIK3CG 203/4885 |
| US-20090215724-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK1 | PIK3CD 115/4885PIK3CA 238/4885PIK3CG 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.